Nurix Therapeutics, Inc. filings document the regulatory record of a clinical-stage biopharmaceutical company focused on targeted protein degradation medicines. Its 8-K reports furnish quarterly and annual financial results, corporate presentations, clinical-program updates for bexobrutideg and pipeline programs, and other material events tied to research, development and financing activity.
The company’s SEC disclosures also cover its common stock listed on the Nasdaq Global Market, shelf registration and at-the-market equity distribution arrangements, underwritten equity offerings, and use-of-proceeds language tied to clinical development and research programs. Proxy and governance filings document board composition, director appointments, compensation programs, committee assignments and annual stockholder meeting matters.
Nurix Therapeutics, Inc. Chief Legal Officer Christine Ring exercised 5,786 stock options on October 2, 2026, at an exercise price of $8.72 per share, acquiring 5,786 common shares. She sold 5,786 common shares that day at a weighted average price of $23.1851 per share; the sale was made under a previously adopted Rule 10b5-1 trading plan. Reported option holdings after the exercise were 111,251.
Christine Ring, identified as an officer of Nurix Therapeutics, Inc., reported a proposed sale of 5,786 common shares with an aggregate market value of $135,045.24. The approximate sale date is October 2, 2026; the securities are described as acquired from the issuer through exercise of stock options, with cash listed as the payment method. Three prior transactions are labeled 10b5-1 sales: 5,787 shares on September 2 and 5,787 and 10,802 shares on August 3. A further sale of 3,847 shares is listed for July 30.
Nurix Therapeutics, Inc. (NRIX) has three reporting persons—Perceptive Advisors LLC, Joseph Edelman, and Perceptive Life Sciences Master Fund, Ltd.—each reporting beneficial ownership of 5,536,629 shares, or 5.3%, with shared voting and dispositive power over those shares. The Master Fund directly holds the 5,536,629 shares. Perceptive Advisors is the Master Fund’s investment manager, and Joseph Edelman is Perceptive Advisors’ managing member; both may be deemed to beneficially own the shares. NRIX had 103,781,683 common shares outstanding as of June 30, 2026.
Nurix Therapeutics, Inc. (NRIX) reported that Chief Legal Officer Christine Ring exercised employee stock options for 5,787 shares of common stock on September 2, 2026 at an exercise price of $8.72 per share, converting them into common stock. These options were part of a grant vesting monthly from March 13, 2024 until February 13, 2027, and following this exercise 117,037 options remain outstanding from the grant. On the same date, she sold 5,387 shares of common stock at a weighted average price of $25.6947 per share and 400 shares at a weighted average price of $26.6375 per share, in each case in transactions carried out under a previously adopted Rule 10b5-1 trading plan.
Nurix Therapeutics, Inc. (NRIX) officer Christine Ring has filed a Form 144 to sell 5,787 shares of common stock of Nurix, expected on September 2, 2026, following an exercise of stock options for cash. The filing also lists multiple prior sales over the past three months, some designated as 10b5-1 plan sales.
Nurix Therapeutics, Inc. (NRIX) reported that Chief Scientific Officer Gwenn Hansen exercised employee stock options for 1,452 shares of common stock at an exercise price of $1.86 per share and on the same date sold 1,452 shares at $25.47 per share. Following the option exercise, Hansen held 60,858 stock options directly, expiring on August 28, 2029. The transactions were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person.
Redmile Group, LLC and related entities report significant ownership in Nurix Therapeutics, Inc. Redmile Group, LLC and its principal, Jeremy C. Green, each report beneficial ownership of 8,782,256 shares of Nurix common stock, representing 8.1% of the class. This stake consists of 4,073,787 outstanding shares and 4,708,469 shares issuable upon exercise of pre-funded warrants held by investment vehicles managed by Redmile. RedCo II Offshore SPV LLC, one such vehicle, reports beneficial ownership of 3,712,546 shares, or 3.5%, including shares issuable upon warrant exercise. Beneficial ownership percentages are based on 103,781,683 shares outstanding as of June 30, 2026, plus the relevant warrant shares. Voting and dispositive powers are reported as shared, with Redmile and Mr. Green disclaiming beneficial ownership beyond their pecuniary interest.
Vestal Point Capital, LP and Ryan Wilder report beneficial ownership of Nurix Therapeutics, Inc. common stock on an amended Schedule 13G. They report beneficial ownership of 8,050,000 shares of common stock, representing 7.8% of the class, based on 103,781,683 shares outstanding as of June 30, 2026. The shares are held by a Vestal Point fund and a managed account, over which the reporting persons have shared voting and dispositive power and no sole power. The filing states it should not be construed as an admission that any reporting person is a beneficial owner for Section 13 purposes.
Rubric Capital Management LP and David Rosen reported beneficial ownership of Nurix Therapeutics, Inc. common stock. They collectively hold 7,227,778 shares of common stock, representing 6.96% of the class. The ownership is held through Rubric Capital–managed funds, including Rubric Capital Master Fund LP, which has rights to receive dividends and sale proceeds on more than 5% of the shares.
The percentage ownership is based on 103,781,683 shares outstanding of Nurix common stock as of June 30, 2026, as referenced from the company’s quarterly report. All reported voting and dispositive powers are shared, with no sole voting or dispositive power reported by the filing parties.
T. Rowe Price Associates, Inc. reported beneficial ownership of common stock of Nurix Therapeutics, Inc. (NRIX). The firm reported holding 5,436,587 shares of common stock, representing 5.3% of the outstanding class. It reported sole voting power over 5,250,628 shares and sole dispositive power over 5,436,587 shares, with no shared voting or dispositive power. T. Rowe Price Associates stated that this filing should not be construed as an admission that it is the beneficial owner of these securities and expressly denied such beneficial ownership.